Baidu
map

JACC:使用扩展夹臂进行缘对缘二尖瓣修复

2019-07-25 xiangting MedSci原创

使用扩展夹臂的新二尖瓣修复系统在93%的患者中取得了技术成功。

这项研究目的是探讨使用扩展夹臂进行二尖瓣缘对缘修复的技术成功率和疗效。

MitraClip系统的新版本MitraClip XTR于2018年推出,旨在解决以前版本中观察到的技术限制。

纳入为了治疗症状性二尖瓣返流(MR)接受至少1个新植入物的患者。

本研究纳入的107例患者中(平均年龄76±9岁,69%为男性),MR的病因分布均衡,一半(n=53 [50%])被归类为继发性,其余54例为原发性(n=40 [37%])或混合性(n=14 [13%])。植入装置的平均数量为1.5±0.6。46例患者(43%)需要多装置植入。4例患者发生单小叶装置粘附,另外2例患者发生瓣叶损伤,4例患者需要转为外科手术。102例未行二尖瓣手术治疗的出院存活患者中,95例(93%)MR≤2+,79例(77%)MR≤1+。平均跨瓣梯度从基线时的1.9±1.0mmHg增加到出院时的3.5±1.8mmHg(p<0.001)。

使用扩展夹臂的新二尖瓣修复系统在93%的患者中取得了技术成功。95例患者(93%)MR≤2+,79例患者MR≤1+(77%)。手术失败的主要原因是与小叶受损或孤立小叶损伤相关的急性单叶装置粘附,并且通常需要手术矫正。

原始出处:

Fabien Praz. Edge-to-Edge Mitral Valve Repair With Extended Clip Arms Early Experience From a Multicenter Observational Study. JACC:Cardiovascular Interventions. 22 July 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1735689, encodeId=02541e3568910, content=<a href='/topic/show?id=be5123894c6' target=_blank style='color:#2F92EE;'>#二尖瓣修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23894, encryptionId=be5123894c6, topicName=二尖瓣修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2033947151, createdName=fengyi823, createdTime=Wed Jan 08 07:28:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854461, encodeId=12a618544616d, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat May 02 13:28:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326286, encodeId=3f9213262861a, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 27 02:28:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463256, encodeId=b67414632563b, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Sat Jul 27 02:28:00 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1735689, encodeId=02541e3568910, content=<a href='/topic/show?id=be5123894c6' target=_blank style='color:#2F92EE;'>#二尖瓣修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23894, encryptionId=be5123894c6, topicName=二尖瓣修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2033947151, createdName=fengyi823, createdTime=Wed Jan 08 07:28:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854461, encodeId=12a618544616d, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat May 02 13:28:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326286, encodeId=3f9213262861a, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 27 02:28:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463256, encodeId=b67414632563b, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Sat Jul 27 02:28:00 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
    2020-05-02 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1735689, encodeId=02541e3568910, content=<a href='/topic/show?id=be5123894c6' target=_blank style='color:#2F92EE;'>#二尖瓣修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23894, encryptionId=be5123894c6, topicName=二尖瓣修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2033947151, createdName=fengyi823, createdTime=Wed Jan 08 07:28:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854461, encodeId=12a618544616d, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat May 02 13:28:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326286, encodeId=3f9213262861a, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 27 02:28:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463256, encodeId=b67414632563b, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Sat Jul 27 02:28:00 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1735689, encodeId=02541e3568910, content=<a href='/topic/show?id=be5123894c6' target=_blank style='color:#2F92EE;'>#二尖瓣修复#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23894, encryptionId=be5123894c6, topicName=二尖瓣修复)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e2033947151, createdName=fengyi823, createdTime=Wed Jan 08 07:28:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854461, encodeId=12a618544616d, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat May 02 13:28:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326286, encodeId=3f9213262861a, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Jul 27 02:28:00 CST 2019, time=2019-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463256, encodeId=b67414632563b, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Sat Jul 27 02:28:00 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
    2019-07-27 wwzzly

相关资讯

JACC:经导管二尖瓣修复的机构经验和临床结局

对于使用MitraClip的经导管二尖瓣修复,机构经验增加与手术成功率、手术时间和手术并发症的改善相关。

JACC:ACC发布二尖瓣反流共识:MitraClip要严格限制

近日,基于2014年美国心脏协会和美国心脏病学院(AHA/ACC)联合发布的瓣膜病临床管理指南和其最新更新,ACC发布了最新的二尖瓣反流临床管理路径决策共识。

Circulation:经导管治疗缘到缘重度三尖瓣反流:MitraClip技术

使用MitraClip系统进行TR的导管治疗在这个预选患者队列中是安全可行的。初步功效分析显示TR的显著减轻可能会导致临床结局的改善。

Circulation:MitraClip®用于功能性二尖瓣返流的一年预后

在继发性MR患者中使用MitraClip进行经导管MV修复与可接受的安全性、MR严重程度的降低、症状改善和积极的心室重构相关。

Heart:手术高危患者经导管减少明显二尖瓣返流的5年预后

EVEREST II HRS证实了MitraClip在手术高危患者中5年的长期安全性和疗效。

葛均波:2018年介入心脏病年度盘点

转眼间一年就要过去了,现将2018年心血管介入治疗领域可能改变目前临床实践的重要研究和亮点研究回顾如下。

Baidu
map
Baidu
map
Baidu
map